Moreover, the 36-month beta value for ARWR is 0.96. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for ARWR is 117.77M and currently, short sellers hold a 7.53% of that float. On May 10, 2024, ARWR’s average trading volume was 1.21M shares.
ARWR) stock’s latest price update
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)’s stock price has decreased by -1.98 compared to its previous closing price of 25.22. However, the company has seen a 2.45% increase in its stock price over the last five trading sessions. Business Wire reported 2024-04-24 that PASADENA, Calif.–(BUSINESS WIRE)—- $arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 9, 2024, at 4:30 p.m. ET to discuss its financial results for the fiscal second quarter ended March 31, 2024. Webcast and Conference Call and Details Investors may access a live audio webcast on the Company’s website at https://ir.arrowheadpharma.com/events-and-presentations. A replay of the webcast will be available approximately two hours aft.
ARWR’s Market Performance
ARWR’s stock has risen by 2.45% in the past week, with a monthly drop of -2.64% and a quarterly drop of -19.87%. The volatility ratio for the week is 3.58% while the volatility levels for the last 30 days are 4.55% for Arrowhead Pharmaceuticals Inc. The simple moving average for the past 20 days is 4.44% for ARWR’s stock, with a -13.54% simple moving average for the past 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with BofA Securities repeating the rating for ARWR by listing it as a “Buy.” The predicted price for ARWR in the upcoming period, according to BofA Securities is $29 based on the research report published on December 04, 2023 of the previous year 2023.
Citigroup, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $33. The rating they have provided for ARWR stocks is “Neutral” according to the report published on September 19th, 2023.
ARWR Trading at -8.56% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.12% of loss for the given period.
Volatility was left at 4.55%, however, over the last 30 days, the volatility rate increased by 3.58%, as shares sank -3.74% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.29% lower at present.
During the last 5 trading sessions, ARWR rose by +2.45%, which changed the moving average for the period of 200-days by -30.60% in comparison to the 20-day moving average, which settled at $23.62. In addition, Arrowhead Pharmaceuticals Inc. saw -19.22% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Vakiener Victoria, who sale 1,799 shares at the price of $23.31 back on May 02 ’24. After this action, Vakiener Victoria now owns 30,205 shares of Arrowhead Pharmaceuticals Inc., valued at $41,935 using the latest closing price.
Hamilton James C, the Chief Discovery/Trans Medicine of Arrowhead Pharmaceuticals Inc., sale 6,000 shares at $28.03 during a trade that took place back on Apr 01 ’24, which means that Hamilton James C is holding 204,851 shares at $168,180 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -1.65 for the present operating margin
- 0.92 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -1.63. The total capital return value is set at -0.53. Equity return is now at value -110.45, with -39.11 for asset returns.
Based on Arrowhead Pharmaceuticals Inc. (ARWR), the company’s capital structure generated 0.43 points at debt to capital in total, while cash flow to debt ratio is standing at -1.65. The debt to equity ratio resting at 0.74. The interest coverage ratio of the stock is -14.36.
Currently, EBITDA for the company is -188.16 million with net debt to EBITDA at -0.22. When we switch over and look at the enterprise to sales, we see a ratio of 17.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.73.
Conclusion
To wrap up, the performance of Arrowhead Pharmaceuticals Inc. (ARWR) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
